Nuclear Medicine: Page 388

Fujisawa, Bristol-Myers Squibb ink promotion deal

By AuntMinnie.com staff writers

Bristol-Myers Squibb Medical Imaging and Fujisawa Healthcare have entered into a co-promotion agreement in the U.S. for Fujisawa’s Adenoscan.

October 20, 2003

Detection of occult metastases in head and neck cancer feasible with SLN biopsy

By Edward Susman

Sentinel nodes can be readily identified during head and neck surgery by using a radionuclide-labeled colloid, according to presenters at the 2003 American Academy of Otolaryngology-Head and Neck Surgery Foundation meeting in Orlando, FL. In addition, careful dissection of the nodes appears to correlate with full neck dissection.

October 19, 2003

GE rumored to be courting Amersham

By AuntMinnie.com staff writers

GE Medical Systems parent General Electric has reportedly made an overture to British pharmaceutical firm Amersham, according to an article in the Wall Street Journal.

October 9, 2003

Nuclear medicine specialists find success with corn-fed cholescintigraphy

By Shalmali Pal

Dr. Grant Eiselen and Dr. Stephen Ferrante at Rochester General Hospital in New York turned to dietary corn for diagnosing gallbladder dyskinesia when the synthetic form of cholecystokinin (CCK) became unavailable.

October 2, 2003

Draxis scores patent

By AuntMinnie.com staff writers

Radiopharmaceutical developer DraxImage has received a U.S. patent for a family of chelating compounds that could be used in the development of imaging and radiotherapeutic agents.

October 1, 2003

Molecular Imaging Radiology Insider

By Jonathan S. Batchelor

Physicians who diagnose gall bladder dyskinesia will remember 2001 as the year Bristol-Myers Squibb turned off the tap on Kinevac, a synthetic cholecystokinin drug used in cholescintigraphy. A year later, in December 2002, Bracco Diagnostics resumed manufacturing and marketing the product.

September 28, 2003